To identify tumor genes that could be involved in the in vivo adaptation to everolimus and the prevention of such adaptation by CDK8/19i, we selected differentially expressed genes (DEGs) affected by different treatments using a 1.5-fold change of median gene expression and false discovery rate (FDR) <0.05 as cutoffs for DEG selection. The gene discussed is CDK8; the disease is neoplasm.